Immunovirologic characteristics of human immunodeficiency virus-infected patients consisting mainly of injecting drug users on highly active antiretroviral treatment with prolonged virologic failure

Viral Immunology

Volumn 19, Issue 4, 2006, Pages 759-767

  Vallejo, Alejandro ^a   Ruiz Mateos, Ezequiel ^a,b   Molina Pinelo, Sonia ^a   Soriano Sarabia, Natalia ^a   De Felipe, Beatriz ^a   Gutierrez, Sonia ^a   Sánchez Quijano, Armando ^a   Lissen, Eduardo ^a   Leal, Manuel ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG TREATMENT FAILURE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ABUSE; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PHENOTYPE; RETROSPECTIVE STUDY; VIRUS IMMUNITY; VIRUS ISOLATION; VIRUS MUTATION; VIRUS STRAIN; VIRUS VIRULENCE;

HUMAN IMMUNODEFICIENCY VIRUS;

ADULT; AMINO ACID SEQUENCE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CROSS-SECTIONAL STUDIES; FEMALE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RETROSPECTIVE STUDIES; SUBSTANCE ABUSE, INTRAVENOUS; TREATMENT FAILURE; VIRAL LOAD;

EID: 33846083898     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2006.19.759     Document Type: Article

References (21)

1. Zolopa AR: Genotype-phenotype discordance: The evolution in our understanding HIV-1 drug resistance. AIDS 2003;17:1077-1078.
2. Zaccarelli M, Perno CF, Forbici F, Cingolani A, Liuzzi G, Bertoli A, Trotta MP, Bellocchi MC, Di Giambenedetto S, Tozzi V, Gori C, D'Arrigo R, De Longis P, Noto P, Girardi E, De Luca A, and Antinori A: Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation. Antivir Ther 2003;8:51-56.
3. Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, Albrecht MA; ACTG 364 Study Team. Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS 2003;17:821-830.
4. Cozzi-Lepri A, Phillips AN, Miller V, Katlama C, Ledergerber B, Vella S, Weber J, Bruun JN, Kirk O, Clotet B, and Lundgrens JD: Changes in viral load in people with virological failure who remain on the same HAART regimen. Antivir Ther 2003;8:127-136.
5. Nicastri E, Sarmati L, d'Ettorre G, Palmisano L, Parisi SG, Uccella I, Rianda A, Concia E, Vullo V, Vella S, and Andreoni M: Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy. J Med Virol 2003;69:1-6.
6. Delforge ML, Liesnard C, Debaisieux L, Tchetcheroff M, Farber CM, and Van Vooren JP: In vivo inhibition of syncytium-inducing variants of HIV in patients treated with didanosine. AIDS 1995;9:89-90.
7. Connor RI, Sheridan KE, Ceradini D, Choe S, and Landau NR: Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997;185:621-628.
8. Karlsson A, Parsmyr K, Sandstrom E, Fenyö EM, and Albert J: MT-2 cell tropism as prognostic marker for disease progression in human immunodeficiency virus type 1 infection. J Clin Microbiol 1994;32:364-370.
9. Xiao L, Rudolf DL, Owen SM, Spira TJ, and Lal RB: Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV disease progression. AIDS 1998;12:F137-F143.
10. Sugiura W, Matsuda Z, Yokomaku Y, Hertogs K, Larder B, Oishi T, Okano A, Shiino T, Tatsumi M, Matsuda M, Abumi H, Takata N, Shirahata S, Yamada K, Yoshikura H, and Nagai Y: Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 2002;46:708-715.
11. Polzer S, Dittmar M, Schmitz H, and Schreiber M: The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization. Virology 2002;304:70-80.
12. Barbour JD, Wrin T, Grant RM, Martin JN, Segal MR, Petropoulos CJ, and Deeks SG: Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol 2002;76:11104-11112.
13. Deval J, Navarro JM, Selmi B, Courcambeck J, Boretto J, Half on P, Garrido-Urbani S, Sire J, and Canard B: A loss of viral replicative capacity correlates with altered DNA polymerisation kinetics by the human immunodeficiency virus reverse transcriptase bearing the K65R and L74V dideoxynucleoside resistance substitutions. J Biol Chem 2004;279:25489-25496.
14. Diallo K, Marchand B, Wei X, Cellai L, Gotte M, and Wainberg M: Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity. J Virol 2003;77:8621-8632.
15. Devereux HL, Emery VC, Johnson MA, and Loveday C: Replicative fitness in vivo of HIV-1 variants with multiple drug resistance-associated mutations. J Med Virol 2001;2:218-224.
16. Collins JA, Thompson MG, Paintsil E, Ricketts M, Gedzior J, and Alexander L: Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants. J Virol 2004;78:603-611.
17. Bangsberg DR, Acosta EP, Gupta R, Guzman D, Riley ED, and Harrigan PR: Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006;20:223-231.
18. Philpott S, Weiser B, Anastos K, Kitchen CM, Robison E, Meyer WA, Sacks HS, Mathur-Wagh U, Brunner C, and Burger H: Preferential suppression of CXCR4-specific strains of HIV-1 by antiviral therapy. J Clin Invest 2001;107:431-438.
19. Skrabal K, Trouplin V, Labrose B, Obry V, Damond F, Hance AJ, Clavel F, and Mammano F: Impact of antiretroviral treatment on the tropism of HIV-1 plasma virus populations. AIDS 2003;17:809-814.
20. Holtkamp N, Otteken A, Findhammer S, Miller V, Kurth R, and Werner A: Unexpected coreceptor usage of primary human immunodeficiency virus type 1 isolates from viremic patients under highly active antiretroviral therapy. J Infect Dis 2000;181:513-521.
21. Ercoli L, Sarmati L, Nicastri E, Giannini G, Galluzzo C, Vella S, and Andreoti M: HIV phenotype switching during antiretroviral therapy: Emergence of saquinavir-resistant strains with less cytopathogenicity. AIDS 1997;11:1211-1217.